Markets
Businessman Wondering How Low It Can Go
Getty Images
Weird Money

We're in a godawful vintage for venture funds

Data from Carta shows that venture funds launched in 2021 and 2022 are struggling.

Jack Raines
8/20/24 2:20PM

Equity management platform Carta published a detailed report on the state of venture capital through Q1 2024, and the results show that funds launched in 2021 and 2022 are not having a great time. Check these two slides from their report showing median internal rate of return (IRR) and distribution to paid-in capital (DPI) for different vintages over time:

Median IRR Carta
Median DPI Carta

IRR, which is one of the most commonly used performance metrics in venture, measures the returns of a fund while accounting for the time value of cash flows. Through 12 quarters, the median IRR of 2021 funds is negative, while the median IRR for the previous four vintages over the same time period was positive.

The median DPI for 2021 funds is even worse. DPI is the ratio of capital paid out to investors vs. what they invested, and through three years, 2021’s median DPI of 9% is less than half of the median DPI for 2017-2019 funds, and seven percentage points off from 2020.

The TL;DR is that younger funds are underperforming their predecessors by a wide margin.

Why the underperformance, and what does it all mean?

First, the 2021 market was hot, with the exit value in the US VC market hitting a record $797 billion. Thanks to a hot market, it was easier than ever to raise new VC funding, a record $128.3 billion in new venture funding was raised in the US, and 270 first-time funds were launched, the highest number in the last decade.

However, valuations and deal volume collapsed beginning in 2022 as the fed began raising interest rates, with exit value in the US venture market falling from its $797 billion peak in 2021 to just $61.5 billion in 2023. As valuations collapsed, many startups needing new funding were forced to raise down rounds, or funding rounds at lower valuations, and Carta noted that in Q1 2023, almost 20% of all venture investments were down rounds, vs. 5% of deals in 2022.

While funds raised prior to 2021 benefited from high-priced exits in a hot market, funds that launched in 2021 and 2022 have seen their returns struggle as they began deploying capital at market peaks. The biggest losers of this trend are the first-time funds who raised in 2021. While mature firms, who likely exited positions at the market high of 2021, can point to their multi-year track records when raising new funds, first-time venture funds are being judged on their current funds’ performances. Limited partners who invest in first-time venture funds want to see returns before committing to a new fund, and, unless returns improve for 2021 and 2022 funds, many of these first-time funds will struggle to raise new funding in the future.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.